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Abstract: Gaucher disease is an inherited lysosomal storage disorder, characterized by 
deficient activity of glucocerebrosidase leading to storage of glucocerebroside in tissue 
  macrophages. Type I disease, the most prevalent form, lacks central nervous system involve-
ment but presents primarily with variable degrees of hepatosplenomegaly, cytopenia, and bone 
disease. Intravenous enzyme replacement therapy can reverse these manifestations. In addition 
to the two enzymes currently authorized for use, the newest enzyme, taliglucerase alfa, is at 
the late stages of clinical development. Taliglucerase alfa is a unique product, as it is the first 
plant cell–based recombinant enzyme therapy. This review considers the existing evidence for 
therapeutic efficacy of taliglucerase alfa in the treatment of the non-neuronopathic manifesta-
tions of Gaucher disease. Clinical studies encompass one phase I trial in healthy volunteers, one 
phase III trial, and preliminary results from both an extension study and a switch study. In the 
9-month, randomized, double-blind phase III trial, treatment-naïve patients with type I Gaucher 
disease were treated with either 30 or 60 U/kg every 2 weeks. Dose-dependent improvements 
were achieved after 6 and 9 months of therapy, with reductions in spleen and liver volumes 
and improvements in hemoglobin levels. Platelet counts improved initially only in the higher-
dose group, but preliminary results from the extension study also show significant increases 
in the lower-dose group. Bone marrow involvement, as assessed by magnetic resonance imag-
ing, improved in almost all patients. Taliglucerase alfa has shown a good safety profile, with 
few patients experiencing hypersensitivity reactions and developing antibodies. An additional 
enzyme replacement therapy for Gaucher disease would enable the treatment of more patients 
and would provide backup for unexpected production problems. Furthermore, it is expected 
that this new treatment would reduce the costs of therapy. Taliglucerase alfa is a valuable new 
treatment modality for the non-neuronopathic manifestations of Gaucher disease.
Keywords: lysosomal storage disorder, glucocerebrosidase deficiency, enzyme replacement 
therapy, plant-derived recombinant human glucocerebrosidase
Introduction: scope, aims, and objectives
Taliglucerase alfa (Uplyso®; Protalix Biotherapeutics, Karmiel, Israel; Pfizer 
Inc, New York, NY) is a plant-derived recombinant human glucocerebrosidase. 
  Glucocerebrosidase (EC 3.2.1.45) is an acid hydrolase that catalyzes the breakdown 
of glucocerebroside (or glucosylceramide) into glucose and ceramide. Deficiency 
of the enzymatic activity results in buildup of undegraded glucosylceramide in 
macrophages, which causes Gaucher disease.1 Replacement – or, more accurately, 
supplementation – of the deficient enzyme by intravenous administration of gluco-
cerebrosidase, which has a modified glycan structure exposing terminal mannoses, 
has been shown to be safe and effective. The first enzyme preparation that clearly 
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showed reversal of disease manifestations was purified 
from human placental tissue (Ceredase® [alglucerase]; 
Genzyme Corporation, Cambridge, MA).2 This enzyme 
preparation was later replaced by Chinese hamster ovary 
cell–derived recombinant glucocerebrosidase (Cerezyme® 
[imiglucerase]; Genzyme Corporation). Recently, another 
enzyme, produced in a human fibroblast cell line, has 
received marketing authorization (VPRIV® [velaglucerase 
alfa]; Shire Human Genetic Therapies, Cambridge, MA).3 
Taliglucerase alfa is the third enzyme replacement therapy 
for Gaucher disease and the first plant cell–derived human 
enzyme, and it has the potential for large-scale production 
at lower costs compared to the two authorized enzymes.4 
So far, taliglucerase alfa has been submitted for approval to 
the US Food and Drug Administration and has received an 
orphan drug designation at the European Medicines Agency, 
but it has not yet received marketing authorization. This 
review summarizes the evidence for the use of taliglucerase 
alfa to treat type I Gaucher disease (Table 1).
Drug properties and  
mechanism of action
Taliglucerase alfa is a recombinant human glucocerebro-
sidase that is expressed in a plant cell–expression system 
(ProCellEx®; Protalix Biotherapeutics). Within this 
system, it is possible to produce a glycoprotein closely 
resembling human glucocerebrosidase that can be used 
for enzyme replacement therapy. For the plant cell–derived 
  glucocerebrosidase taliglucerase alfa, it has been shown that 
the protein already exposed terminal mannose residues, 
which alleviates the need for post-production processing 
of the glycan   composition.5 Comparison of taliglucerase 
alfa with imiglucerase and velaglucerase alfa shows that 
taliglucerase alfa has two additional amino acids at the 
N-terminus derived from the linker used for the fusion of 
the signal peptide, and it has additional seven amino acids 
at the C-terminus derived from the vacuolar targeting 
signal.5 In addition, the amino acid composition of both 
imiglucerase and taliglucerase alfa differs from the human 
beta-glucocerebrosidase at residue 495, where a mutation 
causes a change from arginine to histidine. Velaglucerase 
alfa has the same amino acid sequence as the human 
enzyme, but X-ray structures of all three enzymes are very 
similar.6 The enzymatic activity of taliglucerase alfa toward 
fluorescent substrate is comparable with imiglucerase, 
and uptake in macrophages is also similar, although the 
uptake of taliglucerase alfa has been reported as enhanced 
at higher   concentrations.5 Taliglucerase alfa differs from 
velaglucerase alfa and imiglucerase with respect to its 
glycosylation, as it contains core alpha-(1,2)-xylose and 
core alpha-(1,3)-fucose,5 which are unique to plant-derived 
proteins. The number of mannose residues is higher for tali-
glucerase alfa than for imiglucerase; no direct comparison is 
made with velaglucerase alfa, which contains longer-chain 
high-mannose-type glycans, compared with the core man-
nose structures found on imiglucerase.6
Drug formulation and dosing
Taliglucerase alfa is available as a lyophilized powder for 
reconstitution, with an enzymatic activity of 200 units per 
vial. Taliglucerase alfa is administered by intravenous infu-
sion over 1–2 hours. Investigated doses are 30–60 U/kg of 
body weight once every 2 weeks.7 A range of doses has been 
investigated in a switch study.8
Table 1 Core evidence clinical impact summary for biweekly intravenous administration of taliglucerase alfa during 9 months of 
therapy for type i Gaucher disease
Outcome measure Evidence Implications
Disease-oriented evidence
  Hepatosplenomegaly Randomized clinical trial with two dose 
regimens3
Significant decrease, indicating reversal  
of primary clinical manifestations
    Specific Gaucher disease  
markers
Significant decrease, indicating clearance  
of storage cells
Patient-oriented evidence
    Hemoglobin levels and  
platelet counts
Randomized clinical trial with two dose  
regimens3
improvement in the majority of patients,  
specifically in the higher-dose group
  Safety 6% infusion reactions; 6% non-neutralizing  
antibodies
Economic evidence
  Cost-effectiveness Unknown As taliglucerase alfa has not yet received a  
marketing authorization, the price is unknown
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Clinical trials
Pharmacokinetics: phase i and iii  
clinical trials
Two safety studies were performed in cynomolgus monkeys. 
In a short, 4-week study with daily administration of tali-
glucerase alfa, no antibodies were detected. In a longer-term, 
39-week study, with biweekly infusions, non-neutralizing 
antibodies could be detected in five of 24 monkeys. No 
infusion-related side effects were observed.9   Pharmacokinetic 
studies in six healthy volunteers revealed a mean half-life 
of 15 minutes (range: 8–32 minutes) at doses of 30 or 
60 U/kg.9 After three weekly infusions, with increasing 
dosages, no antibodies were detected. In the phase III study, 
pharmacokinetics of two doses of enzyme, 30 and 60 U/kg, 
every 2 weeks were studied after the first infusion and after 
38 weeks in 29 patients with Gaucher disease type I. Mean 
maximum plasma concentration, area under the plasma 
concentration-time curve from the time of administration to 
the last measured concentration, and area under the plasma 
concentration-time curve from the time of administration to 
infinity were all higher for patients in the 60 U/kg per infu-
sion group than for those in the 30 U/kg per infusion group.7 
The half-life was similar to what was observed in the healthy 
volunteers. Two patients developed antibodies that were 
non-neutralizing and which did not result in adverse effects.7 
No data have been published on the influence of antibody 
formation on the pharmacokinetic profile.
Safety, tolerability, and clinical efficacy: 
phase iii clinical trial
The phase III clinical trial was a randomized, double-blind, 
parallel-group, safety and efficacy study in treatment-naïve 
patients with type I Gaucher disease.7 Patients eligible for 
the trial were required to have an intact, enlarged spleen, as 
the primary endpoint was the mean decrease in spleen volume. 
By excluding splenectomized patients, a selection is made for 
somewhat less severely affected patients, as splenectomy is 
generally associated with more advanced liver involvement 
and bone complications. Two dosing groups were   evaluated: 
30 and 60 U/kg of body weight once every 2 weeks.   Secondary 
endpoints were a decrease in liver volume, an increase in 
hemoglobin and platelet levels, and a decrease in plasma 
chitotriosidase activity, which is a widely used biochemical 
marker of Gaucher disease.10 The study duration was 9 months. 
Of 33 randomized patients, 16 were allocated to the 30 U/kg 
group and 17 to the 60 U/kg group. Two patients were excluded 
after consent (pregnancy, withdrawal of consent) and   therefore 
efficacy assessments were performed for 15 patients in the 
30 U/kg group and 16 patients in the 60 U/kg group at 6 and 
9 months. The primary endpoint, a reduction of 20% in spleen 
volume, was already met at 6 months. Also, significant reduc-
tions in liver volume were observed, as well as increases in 
hemoglobin level and platelet count. For all parameters studied, 
the higher dose of 60 U/kg led to a more robust response than 
30 U/kg every 2 weeks. This was specifically so for platelet 
responses: although significant increase in platelet count was 
observed in the 60 U/kg group, this was not the case for patients 
in the 30 U/kg group. Chitotriosidase decreased rapidly in a 
dose-dependent manner. The most impressive improvement 
in hemoglobin was that achieved in patients with anemia 
at baseline. This was not the same for platelet response: in 
patients with larger spleens and lower platelet counts, platelet 
responses were generally less impressive. This observation 
has also been made in Gaucher disease patients treated with 
imiglucerase.11 Perhaps the differences in response between 
the two dose groups were related to this phenomenon, as at 
baseline the lower-dose group had more patients with very 
large spleens than the higher-dose group.
No serious adverse events were reported. Two patients 
developed hypersensitivity reactions: one acute reac-
tion after ,5 mL of infusion, which later occurred after 
  imiglucerase infusion as well, and one mast cell–mediated 
reaction.3 Adverse events that were considered to be drug 
related occurred in eight patients (28 events) and included the 
two patients with hypersensitivity reactions. The remaining 
adverse events were variable and included symptoms such 
as abdominal pain, headache, and pruritus, which were all 
mild/moderate and transient.7
Additional studies
In addition to the studies already mentioned, a number of 
other studies have also been performed. Results of these 
studies were presented recently at the Lysosomal Disease 
Network: WORLD Symposium 2012, held February 8–10 in 
San Diego, California. The first study is the extension of 
the phase III clinical trial. Patients could continue treatment 
with taliglucerase alfa, at the same dose received in the trial, 
for an additional 15 months. Twenty-six of the 29 patients 
were followed and these patients demonstrated further 
improvements in all parameters; no new safety concerns were 
reported.12 A press release from Protalix Biotherapeutics, 
published online on February 9, 2012, provided detailed 
data indicating that further spleen volume reductions from 
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baseline were achieved: 54% further reduction in the 60 U/kg 
group and 41% further reduction in the 30 U/kg group.13 
Both dosing groups also demonstrated further reductions 
in liver volume. Hematologic parameters improved as 
well: in patients with anemia at baseline, a further increase 
to 12.9 g/dL was demonstrated. The prolonged period of 
treatment now showed that platelets increased significantly 
in the lower-dose group – from 65,000 to 93,000/mm3 for 
the 30 U/kg group – while further improvements were also 
observed in the 60 U/kg group. The overall positive responses 
were reflected by further reductions in chitotriosidase activ-
ity: by a further 76% in the 60 U/kg group and a further 61% 
in the 30 U/kg group. During this extension period, no serious 
adverse events were reported. Two patients had antibodies; the 
assays used for antibody testing were different from the assay 
used in the initial phase III trial. One patient experienced a 
hypersensitivity reaction after 10 months of therapy, but this 
patient could continue treatment with premedication.
In a separate study, bone marrow responses were evalu-
ated in eight patients from the phase III trial. Quantitative 
chemical shift imaging was performed on lumbar spines 
to assess fat fractions. Previous studies have shown that 
progressive bone marrow infiltration with Gaucher cells in 
untreated patients results in a decrease in adipocytes and thus 
also a decrease in fat fractions.15 This imaging technique 
has been validated in Gaucher disease as an instrument to 
evaluate bone marrow responses to treatment, and increases 
in fat fractions over 12–24 months can typically be observed. 
  Following treatment with taliglucerase alfa, early and sus-
tained increases in bone marrow fat fractions were observed 
in the majority of the patients.16
Whether patients treated with imiglucerase would main-
tain stable disease parameters when switching to taliglucerase 
alfa was studied in a 9-month open-label switchover trial.8 
During this trial, a severe worldwide shortage of imiglucerase 
(Cerezyme) occurred, which meant that many patients had 
their treatment with imiglucerase interrupted or were put 
on lower dosages.17 Therefore the protocol was amended 
to allow assessment of stability based upon pre-shortage 
historical data and to treat a larger number of patients, includ-
ing children. Preliminary results for 26 adult patients were 
reported at the WORLD conference.8 All patients received 
a dose of taliglucerase alfa that was identical to their 
  previous imiglucerase dose, ranging from 10 to 60 U/kg 
every 2 weeks. One patient experienced a hypersensitivity 
reaction. The data showed that mean hemoglobin and platelet 
count and liver and spleen volumes remained stable. From 
the aforementioned Protalix Biotherapeutics press release of 
February 9, 2012, safety analysis showed that taliglucerase 
alfa was well tolerated, and no drug-related serious adverse 
events were reported.13 One patient developed IgG antibodies; 
these antibodies were neutralizing in an in vitro assay but 
negative in a cell-based assay.
Summary of data on antibody  
formation and hypersensitivity
No antibodies were detected in the 4-week phase I monkey 
study with daily administration of taliglucerase alfa. In the 
39-week study, with biweekly infusions, non-neutralizing 
antibodies could be detected in five of 24 monkeys. No 
infusion-related side effects were observed.9 In the healthy 
volunteers, no antibodies were detected after three weekly 
infusions. During the phase III study, two patients developed 
antibodies that were non-neutralizing. New assays were 
developed for the extension phase of this study and during 
the switch study. A total of three patients from all studies 
in Gaucher patients tested positive for neutralizing activity 
in a serum assay but not in a cell-based assay. As described 
earlier, two of these patients were from the phase III exten-
sion trial and one was from the switch trial.13 The patients 
who initially tested positive with the earlier assay now 
tested negative with the new assays.14 In total, two patients 
had hypersensitivity reactions during the first part of the 
phase III study and two other patients had hypersensitivity 
reactions during the extension and the switch studies. Inter-
estingly, hypersensitivity reactions appeared not to be related 
to antibody formation. The clinical impact of the presence 
of antibodies is currently unclear but it does not seem to 
affect clinical outcome.
Place of taliglucerase alfa  
within the treatment arsenal  
for Gaucher disease
Taliglucerase alfa is not yet an authorized treatment for 
Gaucher disease. In 2010, the European Commission granted 
orphan drug designation to taliglucerase alfa, and market-
ing applications for taliglucerase alfa have been filed in 
the United States, Europe, Israel, Brazil, and Australia. An 
important question to consider is whether there is a place 
for another enzyme in the treatment of Gaucher disease. 
  Taliglucerase alfa, as well as the two enzymes currently 
authorized –   imiglucerase and velaglucerase alfa – is inca-
pable of crossing the blood-brain barrier and therefore it is 
specifically indicated for treatment of the type I manifesta-
tions of Gaucher disease – primarily, hepatosplenomegaly, 
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cytopenia, and bone manifestations. Taliglucerase alfa will 
not offer an alternative for the neuronopathic variants of 
the disease. At this point it should be mentioned that there 
are also oral alternatives available: small molecules that 
act as substrate inhibitors. Miglustat (Zavesca®; Actelion 
Pharmaceuticals Limited, Allschwil/Basel, Switzerland) is 
a glucose analogue that can penetrate the central nervous 
system and which has modest effects on Gaucher disease 
  manifestations. However, there is no clear effect on neu-
rological symptoms and it has been authorized for the 
treatment of mild to moderately severe type I Gaucher 
disease.18 A new oral treatment currently being developed, 
eliglustat tartrate (Genzyme Corporation), is hoped to have 
a better efficacy and   toxicity profile, but, unfortunately, it 
cannot access the central nervous system.19 Thus, in the near 
future, five treatments – three enzymes and two substrate 
inhibitors – may become available that only treat the non-
neuronopathic manifestations of Gaucher disease. As the 
majority of Gaucher patients have the non-neuronopathic 
phenotype, a broad arsenal of medication may still be 
important. This became clear during the dramatic shortage 
of imiglucerase (at the time the only authorized enzyme) 
that started in the summer of 2009 and continued, with ups 
and downs, for almost 2 years. Because many patients had 
to reduce or interrupt their therapy, there was a very wel-
come place for alternative enzymes. Although velaglucerase 
alfa has now been authorized, already providing a safe and 
effective alternative, many patients, especially those in 
non-Western countries, still suffer from untreated Gaucher 
disease. Obviously, this involves not only availability of 
enzymes but also, and more specifically, local reimbursement 
policies and facilities to treat and follow patients. In many 
countries, enzymes either cannot be administered, because 
appropriate knowledge and technical support is lacking, 
or cannot be reimbursed. Humanitarian programs, so far 
primarily supported by Genzyme Corporation, have stepped 
in to alleviate at least some of the need of these patients. 
This raises the point that cheaper medication may have a 
profound effect on access to treatment for more patients in 
other countries. The plant cell–derived system used for the 
manufacturing of taliglucerase alfa offers the possibility of 
large-scale production of the enzyme at lower cost. So far, 
the studies have shown that taliglucerase alfa is very effec-
tive, and this effectiveness also covers the extension period 
of the pivotal study, up to 24 months. Based upon the early 
reports, it seems that the safety-benefit ratio may be the same 
as for the two enzymes currently authorized. Perhaps an 
in-depth study on the immunologic effects, including acute 
hypersensitivity reactions, for the three enzymes should 
be performed, so as to identify risk factors that may aid in 
individualizing choice of therapy. In fact, to support indi-
vidual treatment recommendations in the future, comparative 
studies of effectiveness and toxicity should be performed 
for all available therapies. Ideally, an independent commit-
tee should look for long-term outcomes for all treatments, 
as fragmentation of data in different industry-run registries 
hampers comparison of outcomes.20
Conclusion
Taliglucerase alfa has dose-dependent beneficial effects on 
the major manifestations of type I Gaucher disease. The drug 
is very well tolerated and has not led to any serious adverse 
events. Hypersensitivity reactions and antibody formation 
may occur, but it is unclear whether this is different from 
the two enzymes currently authorized. Taliglucerase alfa 
would be a very welcome addition to the treatment arsenal 
for Gaucher disease, as having an additional enzyme replace-
ment therapy would reduce the risk for worldwide shortages 
of authorized enzymes. Furthermore, having an additional 
enzyme replacement therapy may result in cost reduction, 
therefore increasing possibilities for the treatment of patients 
living in less fortunate parts of the world.
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